A Phase 3 clinical trial involving octreotide has reached completed status, according to a record dated November 13, 2026. The study, registered as NCT05459844, is titled "A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs." It compares Lutetium[177Lu] oxodotreotide injection to octreotide LAR in patients with gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. The trial is listed under Phase 3 on ClinicalTrials.gov. Its current status is marked as completed, meaning the study has finished according to the registry entry. No results, outcomes, or efficacy data are included in this status update. The record does not specify findings related to either treatment arm. Octreotide itself remains an approved compound, and this update concerns a separate controlled study using a long acting release formulation as a comparator to the lutetium based agent. Readers should note that completion of a trial reflects its operational status rather than confirmation of any therapeutic benefit or safety outcome. Further details, including any eventual results, would be expected to appear in subsequent updates to the trial record or in related publications. For more background on octreotide, its approved uses, and its regulatory status, readers can consult the compound overview.
Phase 3 Trial Comparing Lutetium Oxodotreotide to Octreotide LAR Completed
See the full octreotide overview
Source: https://clinicaltrials.gov/study/NCT05459844